Investment analysts at StockNews.com assumed coverage on shares of TherapeuticsMD (NASDAQ:TXMD – Get Free Report) in a research note issued on Tuesday. The brokerage set a “hold” rating on the stock.
TherapeuticsMD Price Performance
NASDAQ TXMD opened at $1.32 on Tuesday. TherapeuticsMD has a fifty-two week low of $1.15 and a fifty-two week high of $2.75. The business has a fifty day moving average of $1.52 and a 200-day moving average of $1.72.
Hedge Funds Weigh In On TherapeuticsMD
An institutional investor recently raised its position in TherapeuticsMD stock. Clearline Capital LP raised its stake in TherapeuticsMD, Inc. (NASDAQ:TXMD – Free Report) by 18.9% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 636,622 shares of the company’s stock after acquiring an additional 101,282 shares during the quarter. Clearline Capital LP owned approximately 5.52% of TherapeuticsMD worth $1,025,000 at the end of the most recent quarter. 30.74% of the stock is currently owned by institutional investors and hedge funds.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.
Featured Articles
- Five stocks we like better than TherapeuticsMD
- The 3 Best Fintech Stocks to Buy Now
- Tesla Poised to Hit Record Highs This Holiday Season
- What is a Death Cross in Stocks?
- The Salesforce Rally is Just Getting Started: Here’s Why
- Industrial Products Stocks Investing
- 3 Chip and Data Center Stocks That Can Keep Rising in 2025
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.